Cargando…
Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
It is relatively rare to achieve a median progression-free survival (PFS) of 40 months with pemetrexed monotherapy maintenance, especially in patients with advanced and severe lung cancer. Here, we reported a case of advanced severe lung adenocarcinoma treated with pemetrexed monotherapy maintenance...
Autores principales: | Zhao, Weichao, Zhu, Minli, Wang, Ruijuan, Tong, Zhaohui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072206/ https://www.ncbi.nlm.nih.gov/pubmed/36206106 http://dx.doi.org/10.1097/CAD.0000000000001402 |
Ejemplares similares
-
Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
por: Yoon, Joon‐Young, et al.
Publicado: (2019) -
Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017) -
Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS
por: Liu, Andy, et al.
Publicado: (2023) -
Relationship of driver oncogenes to long term pemetrexed response in non-small cell lung cancer
por: Liang, Ying, et al.
Publicado: (2014) -
Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma
por: Otsuka, Yasuo, et al.
Publicado: (2023)